Retatrutide Get

Primary sources

Every retatrutide citation, annotated

PubMed, ClinicalTrials.gov, and peer-reviewed journals. Every claim on this site traces to one of these sources.

How this reference list works

Every quantitative claim across this site is tagged with an inline citation number [N] that maps to an entry in this list. Citations are drawn from our compiled research corpus for retatrutide (LY3437943, revision 2). Where DOI and PubMed links are available, both are included. ClinicalTrials.gov entries are included for all ongoing Phase 3 trials. No citation in this list was invented; the corpus citation-audit process verified each source's existence and accessibility.

  1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. ↗
  2. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529–544. ↗
  3. Li W, Zhou Q, Cong Z, Yuan Q, Li W, Zhao F, Xu HE, Zhao LH, Yang D, Wang MW. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:77. ↗
  4. Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400:1869–1881. ↗
  5. Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, Haupt A, Hartman ML. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037–2048. ↗
  6. Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide — A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15:796. ↗
  7. Eli Lilly and Company. A Study of Retatrutide (LY3437943) in Participants With Obesity (TRIUMPH-1). ClinicalTrials.gov. 2023. ↗
  8. Eli Lilly and Company. A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3). ClinicalTrials.gov. 2023. ↗
  9. Eli Lilly and Company. The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Function. ClinicalTrials.gov. 2024. ↗
  10. Eli Lilly and Company. A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176). ClinicalTrials.gov. 2024. ↗
  11. Eli Lilly and Company. A Study of LY3437943 in Healthy Participants. ClinicalTrials.gov. 2019. ↗
  12. Bajaj HS, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026. ↗
  13. Elmendorf AJ, et al. IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes. Pharmacological Research. 2026. ↗
  14. et al. The First Triple Agonist for Antiobesity: Retatrutide. Clin Diabetes. 2024. ↗
  15. Drucker DJ, et al. Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. Diabetes Care. 2024. ↗